Home › Multiple Myeloma › District of Columbia
Multiple Myeloma clinical trials in District of Columbia
10 studies for Multiple Myeloma are looking for participants at sites in District of Columbia.
Cities in District of Columbia
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Lombardi Comprehensive Cancer Center, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT04661137A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Georgetown University Medical Center, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06615479Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07555938Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Sibley Memorial Hospital, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328Mosaic Trial for Stem Cell Transplant Recipients
- Georgetown University School of Medicine, Washington D.C.
Recruiting
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06960993Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Sibley Memorial Hospital, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT05243797Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- Cancer Support Community Research & Training Institute, Washington D.C.
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT02333604A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.